NEWSLETTER-2017

449 LEGAL DEVELOPMENTS Ampul, Clexane, Cordarone, Coumadin, Depakin, Dermo- Rest, Delix, Diazomid, Dideral, Dogmatil+Sulpir, Emedur, Excegran, Fasturtec, Flantadatin, Fludara, Furacin, Jevtana, Karvea, Karvezide, Lantus, Muscoril, Nibulan, Nörofren, Paranox, Paranox-S, Plaquenil, Plavix, Bi-Profenid, Ri- lutek, Sabril, Sanasol, Seralin, Sinopryl, Sinoretik, Solian, Surgam, Synvisc, Targocid, Xatral, Prepar, Enterogermina. (23.03.2017, 17-11/130-59) • The Board granted individual exemption to the agreement executed between Daiichi Sankyo İlaç Ticaret Ltd. Şti. and Aksel Ecza Deposu A.Ş. that exclusively authorizes the re- ferred Depot in Turkey for tender sales of the drug called Simdax. (06.04.2017, 17-12/147-66) • The Board granted individual exemption to the Distribution and Device Cooperation Agreement executed between Turk- cell Satış ve Dağıtım Hizmetleri A.Ş., KVK Teknoloji Ürün- leri ve Tic. A.Ş. and Genpa Telekomünikasyon ve İletişim Hizmetleri San. ve Tic. A.Ş. (06.04.2017, 17-12/145-64) • The Board granted individual exemption to the association of undertakings decision regarding carrying out the activities within the scope of “Waste Management Strategies of Worn Tires and Application Plan 2016-2020” prepared by Tire Industrialists Association. (27.04.2017, 17-14/196-82) • The Board granted negative clearance to the lease contract between CarrefourSA Carrefour Sabancı Ticaret Merke- zi A.Ş. and Metro Properties Gayrimenkul Yatırım A.Ş. (24.05.2017, 17-17/254-107) • The Board decided that the DistributorshipAgreement betwe- en Bayer Consumer Care AG and Moltek Sağlık Hizmetleri Üretim ve Pazarlama A.Ş. is not contrary to Law No. 4054, and granted individual exemption to the License Agreement between Bayer Türk Kimya Sanayi Ltd.Şti. and Moltek Sağlık Hizmetleri Üretim ve Pazarlama A.Ş. (08.06.2017, 17-19/289-126)